Gene mutation is considered to be responsible for agnogenic
Cytogenetics of agnogenic
myeloid metaplasia: a study of 61 patients.
Ten patients each with either agnogenic
myeloid metaplasia, polycythemia vera, or primary thrombocytothemia will be given low dose oral interferon alpha daily for 6-12 months as a treatment to relieve the signs and symptoms associated with these disorders.
The cases were divided into posttraumatic group ( n = 257), postoperative group ( n = 8), endogenous group ( n = 2), infectious corneal ulcer group ( n = 1), and agnogenic
group ( n = 3) with regard to etiology.
Immune disorders in agnogenic
myeloid metaplasia: relations to myelofibrosis.
Perirenal extramedullary hematopoiesis in agnogenic
myeloid metaplasia: MR imaging findings.
It is crucial to role out CML by performing the bcr gene rearrangement test, since the therapeutic approach in CML is very different compared to therapy in essential thrombocythemia, polycythemia vera, or agnogenic
myeloid metaplasia with myelofibrosis.
It can be distinguished from agnogenic
myeloid metaplasia by the absence of splenomegaly, teardrop RBCs and leukoerythroblastosis in peripheral blood smears, and from acute megakaryoblastic leukemia by the absence or small percentages of blasts of megakaryocytic origin .